Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diffuse Large B-Cell Lymphoma Pipeline Review, H2 2016, provides an overview of the Diffuse Large B-Cell Lymphoma (Oncology) pipeline landscape.

Diffuse large B-cell lymphoma, a type of non-Hodgkin lymphoma, is a cancer of B-cells. The lymphoma may metastasize to other organs such as the liver, lungs or the bones. The signs and symptoms of diffuse large B-cell lymphoma may include painless swelling in the neck, armpit or groin caused by enlarged lymph nodes, loss of appetite, tiredness, night sweats, unexplained high temperatures, and weight loss. The possible treatments for diffuse large B-cell lymphoma include radiation, chemotherapy, steroid therapy in combination with chemotherapy, high-dose chemotherapy with stem cell support and monoclonal antibody therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diffuse Large B-Cell Lymphoma Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diffuse Large B-Cell Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diffuse Large B-Cell Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Diffuse Large B-Cell Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 57, 38, 30 and 5 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 2, 1 and 1 molecules, respectively for Diffuse Large B-Cell Lymphoma.

Diffuse Large B-Cell Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Diffuse Large B-Cell Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diffuse Large B-Cell Lymphoma (Oncology) therapeutics and enlists all their major an